Autres langues PTC Therapeutics, Inc.

Actions

PTCT

US69366J2006

Produits pharmaceutiques

Temps réel estimé Cboe BZX 21:28:49 11/09/2026			Varia. 5j.	Varia. 1 janv.
66,42 ^USD	-1,42%		-4,28%	-12,67%

24/08	PTC Therapeutics annonce de nouvelles données sur le Sephience confirmant des bénéfices cliniques étendus, notamment un contrôle métabolique durable, une libéralisation du régime alimentaire et un profil de sécurité favorable constant	CI
13/08	Transcript : PTC Therapeutics, Inc. - Special Call

Autres langues

27/08	PTC Therapeutics to Participate in Upcoming Investor Conferences
24/08	Ptc Therapeutics Announces New Sephience Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as Well as Consistent Favorable Safety Profile
24/08	PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
12/08	PTC Therapeutics, Inc. proposed to acquire ST-920 ? a BLA-stage one-time administered AAV gene therapy from Sangamo Therapeutics, Inc. (OTCPK:SGMO.Q) for approximately $210 million.
30/07	PTC Q2 Swings to Profit, Revenue Rises; Ups Guidance
30/07	PTC Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2026
30/07	(PTCT) PTC Therapeutics Expects Full Year 2026 Revenue Range $1.18B - $1.28B, vs. FactSet Est of $1.18B
30/07	Earnings Flash (PTCT) PTC Therapeutics Posts Q2 EPS $0.92, vs. FactSet Est of $0.24
30/07	PTC Therapeutics: Q2 Earnings Snapshot
30/07	Earnings Flash (PTCT) PTC Therapeutics, Inc. Reports Q2 Revenue $360.5M, vs. FactSet Est of $298.6M
30/07	PTC Therapeutics, Inc. Announces Appointment of Hege Sollie-Zetlmayer to Board of Directors, Effective July 28, 2026
30/07	PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
30/07	PTC Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
27/07	PTC Therapeutics' Phenylketonuria Physician Survey Yielded Mixed Results on Sephience Launch Momentum, RBC Says
29/06	PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 2000 Value-Defensive Index
29/06	PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 2000 Growth-Defensive Index
29/06	PTC Therapeutics, Inc.(NasdaqGS:PTCT) added to Russell 2000 Defensive Index
17/06	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16/06	PTC Therapeutics Prices $500 Million Notes Offering
16/06	PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes
15/06	PTC Therapeutics Plans $500 Million Convertible Notes Offering to Refinance 2026 Notes
15/06	PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes
12/06	PTC Therapeutics Insider Sold Shares Worth $1,595,775, According to a Recent SEC Filing
09/06	PTC Therapeutics, Inc. Announces Resignation of Alethia Young from the Board, Effective June 8, 2026
09/06	PTC Therapeutics Shares Rise After Upgrade From Citigroup